1	胡付品, 郭燕, 朱德妹, 等. 2021年CHINET中国细菌耐药监测[J]. 中国感染与化疗杂志, 2022, 22(5): 521-530. 本文引用 [2]

2	CRISTINA LM, GUIJARRO-SÁNCHEZ P, ALONSO-GARCIA I, et al. Epidemiology, resistance genomics and susceptibility of Acinetobacter species: results from the 2020 Spanish nationwide surveillance study[J]. Eurosurveillance, 2024, 29(15): 2300352. 本文引用 [2]

3	DICKSTEIN Y, LELLOUCHE J, SCHWARTZ D, et al. Colistin resistance development following colistin-meropenem combination therapy versus colistin monotherapy in patients with infections caused by carbapenem-resistant organisms[J]. Clin Infect Dis, 2020, 71(10): 2599-2607. 本文引用 [1]

4	罗斌, 李智伟, 王倩, 等. 耐替加环素鲍曼不动杆菌中外排泵AdeB与Bfs过表达生物膜形成的关系[J]. 河北医药, 2023, 45(22): 3399-3402, 3406. 本文引用 [1]

5	陈安林, 陈娅, 陈泽慧,等. 医院感染多重耐药鲍曼不动杆菌患者死亡危险因素的Meta分析[J]. 中国感染控制杂志, 2019, 18(1): 53-58. 本文引用 [1]

6	JIANG M, MU Y, LI N, et al. Carbapenem-resistant Acinetobacter baumannii from air and patients of intensive care units[J]. Pol J Microbiol, 2018, 67(3): 333-338. 本文引用 [1]

7	张馨琢, 江南, 黄永茂, 等. 医院污水中碳青霉烯不敏感菌多样性及碳青霉烯耐药基因研究[J]. 西南医科大学学报, 2018, 41(2): 133-136. 本文引用 [1]

8	柯舒文, 王玉莹, 李浩, 等. 生态环境中抗生素耐药性的产生、传播及影响[J]. 中国医药导报, 2023, 20(21): 49-53. 本文引用 [1]

9	HERNANDO-AMADO S, BLANCO P, ALCALDE-RICO M, et al. Multidrug efflux pumps as main players in intrinsic and acquired resistance to antimicrobials[J]. Drug Resist Updat, 2016, 28: 13-27. 本文引用 [1]

10	ZHENG W, HUANG Y, WU W, et al. Analysis of efflux pump system and other drug resistance related gene mutations in tigecycline-resistant Acinetobacter baumannii [J]. Comput Math Methods Med, 2023, 2023: 8611542. 本文引用 [1]

11	LEE Y, YUM JH, KIM CK, et al. Role of OXA-23 and AdeABC efflux pump for acquiring carbapenem resistance in an Acinetobacter baumannii strain carrying the blaOXA-66 gene[J]. Ann Clin Lab Sci, 2010, 40(1): 43-48. 本文引用 [1]

12	MAGNET S, COURVALIN P, LAMBERT T. Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454[J]. Antimicrob Agents Chemother, 2001, 45(12): 3375-3380. 本文引用 [1]

13

JIA W, LI C, ZHANG H, et al. Prevalence of genes of OXA-23 carbapenemase and AdeABC efflux pump associated with multidrug resistance of Acinetobacter baumannii isolates in the ICU of a comprehensive hospital of Northwestern China[J]. Int J Environ Res Public Health, 2015, 12(8): 10079-10092. 本文引用 [1]

14	HE X, LU F, YUAN F, et al. Biofilm formation caused by clinical Acinetobacter baumannii isolates is associated with overexpression of the AdeFGH efflux pump[J]. Antimicrob Agents Chemother, 2015, 59(8): 4817-4825. 本文引用 [1]

15	VERMA P, TIWARI M, TIWARI V. Efflux pumps in multidrug-resistant Acinetobacter baumannii: Current status and challenges in the discovery of efflux pumps inhibitors[J]. Microb Pathog, 2021, 152: 104766. 本文引用 [1]

16	MIYACHIRO MM, CONTRERAS-MARTEL C, DESSEN A. Penicillin-binding proteins (PBPs) and bacterial cell wall elongation complexes[J]. Subcell Biochem, 2019, 93: 273-289. 本文引用 [1]

17	KAKUTA N, NAKANO R, NAKANO A,et al. A novel mismatched pcr-restriction fragment length polymorphism assay for rapid detection of gyra and parc mutations associated with fluoroquinolone Resistance in Acinetobacter baumannii[J]. Ann Lab Med, 2020, 40(1): 27-32. 本文引用 [1]

18	王忠杰, 阙蜜, 袁喆, 等. 呼吸重症监护室患者感染耐碳青霉烯类肺炎克雷伯菌和死亡危险因素分析[J]. 西南医科大学学报, 2024, 47(2): 147-151. 本文引用 [1]

19

CASTANHEIRA M, COSTELLO SE, WOOSLEY LN, et al. Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases, GES-22 and VIM-35[J]. Antimicrob Agents Chemother, 2014, 58(12): 7358-7366. 本文引用 [1]

20	石娇, 王光西, 丁曼琳, 等. 2014—2018年某三甲医院血流感染分布及革兰阴性菌耐药性分析[J]. 西南医科大学学报, 2020, 43(2): 118-123. 本文引用 [1]

21	COLQUHOUN JM, FAROKHYFAR M, HUTCHESON AR, et al. OXA-23 β-Lactamase overexpression in Acinetobacter baumannii drives physiological changes resulting in new genetic vulnerabilities[J]. mBio, 2021, 12(6): e0313721. 本文引用 [2]

22	瞿巧莉, 李霄, 王鹏飞, 等. 携带不同耐药基因对耐碳青霉烯类肺炎克雷伯菌适应性及毒力的影响[J]. 西部医学, 2024, 36(3): 325-332. 本文引用 [1]

23	IBRAHIM S, AL-SARYI N, AL-KADMY IMS, et al. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals[J]. Mol Biol Rep, 2021, 48(10): 6987-6998. 本文引用 [1]

24	ZHANG X, LI F, AWAN F, et al. Molecular epidemiology and clone transmission of carbapenem-resistant acinetobacter baumannii in icu rooms[J]. Front Cell Infect Microbiol, 2021, 11: 633817. 本文引用 [1]

25	ZHAO YY, ZHU YZ, ZHANG H, et al. Molecular tracking of carbapenem-resistant Acinetobacter baumannii clinical isolates: a multicentre study over a 4-year period across eastern China[J]. J Med Microbiol, 2023, 72(2). 本文引用 [1]

26	殷丽军, 武娜娜, 缪瑾, 等. 2017—2021年某儿科医院耐碳青霉烯类革兰阴性菌综合干预感控措施效果及其耐药基因[J]. 中华医院感染学杂志, 2024, 34(3): 410-415. 本文引用 [1]

27	DEHBANIPOUR R, GHALAVAND Z. Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline[J]. J Clin Pharm Ther, 2022, 47(11): 1875-1884. 本文引用 [1]

28	NOVOVIĆ K, MIHAJLOVIĆ S, DINIĆ M, et al. Acinetobacter spp. porin Omp33-36: classification and transcriptional response to carbapenems and host cells[J]. PLoS One, 2018, 13(8): e0201608. 本文引用 [1]

29	SHENKUTIE AM, YAO MZ, SIU GK, et al. Biofilm-induced antibiotic resistance in clinical Acinetobacter baumannii isolates[J]. Antibiotics (Basel), 2020, 9(11): E817. 本文引用 [1]

30	VERSTRAETEN N, BRAEKEN K, DEBKUMARI B, et al. Living on a surface: swarming and biofilm formation[J]. Trends Microbiol, 2008, 16(10): 496-506. 本文引用 [1]

31	RANJBAR A, RASOOLI I, JAHANGIRI A, et al. Specific egg yolk antibody raised to biofilm associated protein (Bap) is protective against murine pneumonia caused by Acinetobacter baumannii[J]. Sci Rep, 2022, 12: 12576. 本文引用 [1]

32	NOGBOU ND, RAMASHIA M, NKAWANE GM, et al. Whole-genome sequencing of a colistin-resistant Acinetobacter baumannii strain isolated at a tertiary health facility in Pretoria, South Africa[J]. Antibiotics (Basel), 2022, 11(5): 594. 本文引用 [1]

33	NIE D, HU Y, CHEN Z, et al. Outer membrane protein A (OmpA) as a potential therapeutic target for Acinetobacter baumannii infection[J]. J Biomed Sci, 2020, 27(1): 26. 本文引用 [1]

34	GADDY JA, TOMARAS AP, ACTIS LA. The Acinetobacter baumannii 19606 OmpA protein plays a role in biofilm formation on abiotic surfaces and in the interaction of this pathogen with eukaryotic cells[J]. Infect Immun, 2009, 77(8): 3150-3160. 本文引用 [1]

35	NIU T, GUO L, LUO Q, et al. Wza gene knockout decreases Acinetobacter baumannii virulence and affects Wzy-dependent capsular polysaccharide synthesis[J]. Virulence, 2020, 11(1): 1-13. 本文引用 [1]

36	MUKHERJEE S, BASSLER BL. Bacterial quorum sensing in complex and dynamically changing environments[J]. Nat Rev Microbiol, 2019, 17: 371-382. 本文引用 [1]

37	HETTA HF, AL-KADMY IMS, KHAZAAL SS, et al. Antibiofilm and antivirulence potential of silver nanoparticles against multidrug-resistant Acinetobacter baumannii [J]. Sci Rep, 2021, 11: 10751. 本文引用 [1]

38	ZENG L, LIN F, LING B. Effect of traditional Chinese medicine monomers interfering with quorum-sensing on virulence factors of extensively drug-resistant Acinetobacter baumannii [J]. Front Pharmacol, 2023, 14: 1135180. 本文引用 [1]

39	ZHONG S, HE S. Quorum sensing inhibition or quenching in Acinetobacter baumannii: the novel therapeutic strategies for new drug development[J]. Front Microbiol, 2021, 12: 558003. 本文引用 [1]

40	周华, 周建英, 俞云松. 中国鲍曼不动杆菌感染诊治与防控专家共识解读[J]. 中国循证医学杂志, 2016, 16(1): 26-29. 本文引用 [1]

41	KARLOWSKY JA, HACKEL MA, MCLEOD SM, et al. In vitro activity of sulbactam-durlobactam against global isolates of Acinetobacter baumannii-calcoaceticus complex collected from 2016 to 2021[J]. Antimicrob Agents Chemother, 2022, 66(9): e0078122. 本文引用 [1]

42	曾玫, 夏君, 宗志勇, 等. 碳青霉烯类耐药革兰阴性菌感染的诊断、治疗及防控指南[J]. 中国感染与化疗杂志, 2024, 24(2): 135-151. 本文引用 [1]

43	LENHARD JR, SMITH NM, BULMAN ZP, et al. High-dose ampicillin-sulbactam combinations combat polymyxin-resistant Acinetobacter baumannii in a hollow-fiber infection model[J]. Antimicrob Agents Chemother, 2017, 61(3): e01268-16. 本文引用 [1]

44	KARVOUNIARIS M, ALMYROUDI MP, ABDUL-AZIZ MH, et al. Novel antimicrobial agents for gram-negative pathogens[J]. Antibiotics (Basel), 2023, 12(4): 761. 本文引用 [1]

45	LIVERMORE DM, MUSHTAQ S, WARNER M, et al. In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2016, 60(6): 3840-3844. 本文引用 [1]

46	ZHANEL GG, ESQUIVEL J, ZELENITSKY S, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent[J]. Drugs, 2020, 80(3): 285-313. 本文引用 [1]

47	冯广伟. 头孢地尔对产金属β-内酰胺酶革兰阴性菌的作用现状研究[J]. 中国现代药物应用, 2024, 18(3): 170-174. 本文引用 [1]

48	VIALE P, SANDROCK CE, RAMIREZ P, et al. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence[J]. Ann Intensive Care, 2023, 13(1): 52. 本文引用 [1]

49

BASSETTI M, ECHOLS R, MATSUNAGA Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial[J]. Lancet Infect Dis, 2021, 21(2): 226-240. 本文引用 [1]

50	FALCONE M, TISEO G, LEONILDI A, et al. Cefiderocol- compared to colistin-based regimens for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii [J]. Antimicrob Agents Chemother, 2022, 66(5): e0214221. 本文引用 [1]

51	KEAM SJ. Sulbactam/durlobactam: first approval[J]. Drugs, 2023, 83(13): 1245-1252. 本文引用 [1]

52

KAYE KS, SHORR AF, WUNDERINK RG, et al. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii–calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)[J]. Lancet Infect Dis, 2023, 23(9): 1072-1084. 本文引用 [1]

53	DURAND-RÉVILLE TF, GULER S, COMITA-PREVOIR J, et al. ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii [J]. Nat Microbiol, 2017, 2: 17104. 本文引用 [1]

54	ABDUL-MUTAKABBIR JC, OPOKU NS, TAN KK, et al. Determining susceptibility and potential mediators of resistance for the novel polymyxin derivative, SPR206, in Acinetobacter baumannii [J]. Antibiotics (Basel), 2024, 13(1): 47. 本文引用 [1]

55	ASLAN AT, AKOVA M, PATERSON DL. Next-generation polymyxin class of antibiotics: a ray of hope illuminating a dark road[J]. Antibiotics (Basel), 2022, 11(12): 1711. 本文引用 [1]

56	GORDILLO ALTAMIRANO F, FORSYTH JH, PATWA R, et al. Bacteriophage-resistant Acinetobacter baumannii are resensitized to antimicrobials[J]. Nat Microbiol, 2021, 6: 157-161. 本文引用 [1]

57	MAJKOWSKA-SKROBEK G, MARKWITZ P, SOSNOWSKA E, et al. The evolutionary trade-offs in phage-resistant Klebsiella pneumoniae entail cross-phage sensitization and loss of multidrug resistance[J]. Environ Microbiol, 2021, 23(12): 7723-7740. 本文引用 [1]

58	EROL HB, KASKATEPE B, YILDIZ S, et al. The effect of phage-antibiotic combination strategy on multidrug-resistant Acinetobacter baumannii biofilms[J]. J Microbiol Meth, 2023, 210: 106752. 本文引用 [1]

59	SZAŁAJ N, BENEDIKTSDOTTIR A, RUSIN D, et al. Bacterial type I signal peptidase inhibitors - Optimized hits from nature[J]. Eur J Med Chem, 2022, 238: 114490. 本文引用 [1]

60	ALLSOP A, BROOKS G, EDWARDS PD, et al. Inhibitors of bacterial signal peptidase: a series of 6-(substituted oxyethyl)penems[J]. J Antibiot (Tokyo), 1996, 49(9): 921-928. 本文引用 [1]

61	PERSONNE Y, CURTIS MA, WAREHAM DW, et al. Activity of the type I signal peptidase inhibitor MD3 against multidrug-resistant Gram-negative bacteria alone and in combination with colistin[J]. J Antimicrob Chemother, 2014, 69(12): 3236-3243. 本文引用 [1]

62	CRANEY A, ROMESBERG FE. The inhibition of type I bacterial signal peptidase: biological consequences and therapeutic potential[J]. Bioorg Med Chem Lett, 2015, 25(21): 4761-4766. 本文引用 [1]

63	LIU W, WU Z, MAO C, et al. Antimicrobial peptide Cec4 eradicates the bacteria of clinical carbapenem-resistant Acinetobacter baumannii biofilm[J]. Front Microbiol, 2020, 11: 1532. 本文引用 [1]

64	PENG SY, YOU RN, LAI MJ, et al. Highly potent antimicrobial modified peptides derived from the Acinetobacter baumannii phage endolysin LysAB2[J]. Sci Rep, 2017, 7: 11477.

65	LOOD R, WINER BY, PELZEK AJ, et al. Novel phage lysin capable of killing the multidrug-resistant gram-negative bacterium Acinetobacter baumannii in a mouse bacteremia model[J]. Antimicrob Agents Chemother, 2015, 59(4): 1983-1991.

66	FENG XR, SAMBANTHAMOORTHY K, PALYS T, et al. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii [J]. Peptides, 2013, 49: 131-137. 本文引用 [1]

67	ALSAAB FM, DEAN SN, BOBDE S, et al. Computationally designed AMPs with antibacterial and antibiofilm activity against MDR Acinetobacter baumannii [J]. Antibiotics (Basel), 2023, 12(9): 1396. 本文引用 [1]

68	LIM J, MYUNG H, LIM D, et al. Antimicrobial peptide thanatin fused endolysin PA90 (Tha-PA90) for the control of Acinetobacter baumannii infection in mouse model[J]. J Biomed Sci, 2024, 31(1): 36. 本文引用 [1]

69	WATKINS RR. A formidable foe: carbapenem-resistant Acinetobacter baumannii and emerging nonantibiotic therapies[J]. Expert Rev Anti Infect Ther, 2018, 16(8): 591-593. 本文引用 [1]

70	LEUNG V, VINCENT C, EDENS TJ, et al. Antimicrobial resistance gene acquisition and depletion following fecal microbiota transplantation for recurrent Clostridium difficile infection[J]. Clin Infect Dis, 2018, 66(3): 456-457. 本文引用 [2]

71	WAN G, RUAN L, YIN Y, et al. Effects of silver nanoparticles in combination with antibiotics on the resistant bacteria Acinetobacter baumannii [J]. Int J Nanomedicine, 2016, 11: 3789-3800. 本文引用 [1]

72	LI XS, GUI R, LI J, et al. Novel multifunctional silver nanocomposite serves as a resistance-reversal agent to synergistically combat carbapenem-resistant Acinetobacter baumannii [J]. ACS Appl Mater Interfaces, 2021, 13(26): 30434-30457. 本文引用 [1]

73	LIU C, CHEN K, WU Y, et al. Epidemiological and genetic characteristics of clinical carbapenem-resistant Acinetobacter baumannii strains collected countrywide from hospital intensive care units (ICUs) in China[J]. Emerg Microbes Infect, 2022, 11(1): 1730-1741. 本文引用 [1]

74	ZHENG Y, XU N, PANG J, et al. Colonization with extensively drug-resistant Acinetobacter baumannii and prognosis in critically ill patients: an observational cohort study[J]. Front Med (Lausanne), 2021, 8: 667776. 本文引用 [1]

75	祝司霞, 庞载元. 泛耐药鲍曼不动杆菌呼吸道定植如何管理?[J]. 中国全科医学, 2019, 22(27): 3286-3291. 本文引用 [1]

76	BRINDLE T. Horizontal approaches to infection prevention: daily chlorhexidine gluconate bathing[J]. Br J Nurs, 2023, 32(11): 502-507. 本文引用 [1]

77	PALLOTTO C, FIORIO M, DE ANGELIS V, et al. Daily bathing with 4% chlorhexidine gluconate in intensive care settings: a randomized controlled trial[J]. Clin Microbiol Infect, 2019, 25(6): 705-710. 本文引用 [2]

78	NOTO MJ, DOMENICO HJ, BYRNE DW, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial[J]. JAMA, 2015, 313(4): 369-378. 本文引用 [1]

79	TACCONELLI E, MAZZAFERRI F, DE SMET AM, et al. ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers[J]. Clin Microbiol Infect, 2019, 25(7): 807-817. 本文引用 [1]

80	KREITMANN L, HELMS J, MARTIN-LOECHES I, et al. ICU-acquired infections in immunocompromised patients[J]. Intensive Care Med, 2024, 50(3): 332-349. 本文引用 [1]

81	ZENG X, WANG N, XIANG CY, et al. Peptidoglycan-associated lipoprotein contributes to the virulence of Acinetobacter baumannii and serves as a vaccine candidate[J]. Genomics, 2023, 115(2): 110590. 本文引用 [2]

82	DOLLERY SJ, ZURAWSKI DV, BUSHNELL RV, et al. Whole-cell vaccine candidates induce a protective response against virulent Acinetobacter baumannii [J]. Front Immunol, 2022, 13: 941010. 本文引用 [1]

83	AINSWORTH S, KETTER PM, YU JJ, et al. Vaccination with a live attenuated Acinetobacter baumannii deficient in thioredoxin provides protection against systemic Acinetobacter infection[J]. Vaccine, 2017, 35(26): 3387-3394. 本文引用 [1]

84	HU Y, ZHANG X, DENG S, et al. Non-antibiotic prevention and treatment against Acinetobacter baumannii infection: are vaccines and adjuvants effective strategies?[J]. Front Microbiol, 2023, 14: 1049917. 本文引用 [1]

85	HOSSEINNEZHAD-LE, DOOSTI A, SHARIFZADEH A. Novel csuC-DNA nanovaccine based on chitosan candidate vaccine against infection with Acinetobacter baumannii [J]. Vaccine, 2023, 41(13): 2170-2183. 本文引用 [1]

86	YANG N, JIN X, ZHU C, et al. Subunit vaccines for Acinetobacter baumannii [J]. Front Immunol, 2022, 13: 1088130. 本文引用 [1]

87	NAGHIPOUR ERAMI A, RASOOLI I, JAHANGIRI A, et al. Anti-Omp34 antibodies protect against Acinetobacter baumannii in a murine sepsis model[J]. Microb Pathog, 2021, 161: 105291. 本文引用 [1]

88	RUSSO TA, BEANAN JM, OLSON R, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization[J]. Infect Immun, 2013, 81(3): 915-922. 本文引用 [1]

89	王纯睿, 袁喆, 周泓羽, 等. 重症监护病房肺炎克雷伯菌临床特点及耐药分析[J]. 西部医学, 2019, 31(4): 535-539. 本文引用 [1]

90	World Health Organization. Guidelines on core components of infection prevention and control programmes at the national and acute health care facility level [EB/OL]. [2024-10-15]. https://www.who.int/publications/i/item/9789241549929 本文引用 [1]